{
    "clinical_study": {
        "@rank": "157894", 
        "acronym": "ReLive", 
        "arm_group": [
            {
                "arm_group_label": "Doxorubicin Transdrug (DT) at 20mg/m2", 
                "arm_group_type": "Experimental", 
                "description": "DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or toxicity"
            }, 
            {
                "arm_group_label": "Doxorubicin Transdrug (DT) at 30 mg/m2", 
                "arm_group_type": "Experimental", 
                "description": "DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or toxicity"
            }, 
            {
                "arm_group_label": "Best Supportive Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients randomized in the control group  will receive treatment according to the investigator's choice, until disease progression or toxicity"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is\n      effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma\n      (HCC) after failure or intolerance to Sorafenib. Patients with HCC with or without cirrhosis\n      and with good liver functions are eligible. Only those who can not benefit from treatment\n      for which efficacy is demonstrated are eligible.\n\n      These patients are usually proposed either best supportive care (BSC) or participation to\n      clinical trials. Patients eligible for the RELIVE study will receive either DT at 20 mg/m2\n      or DT at 30 mg/m2 or the BSC."
        }, 
        "brief_title": "Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Stress, Psychological", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "Doxorubicin-Transdrug\u2122 (DT) is a nanoparticle formulation of doxorubicin.In in vitro and in\n      vivo models, DT was shown to overcome the multidrug resistance (MDR) and to be more\n      effective than doxorubicin on both sensitive and resistant tumour models and in particular\n      in the X/myc bi-transgenic MDR murine model of HCC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant, non-breast feeding female;\n\n          -  Aged \u2265 18 years;\n\n          -  Patient with:\n\n               -  advanced HCC (BCLC-C according to BCLC staging classification) having progressed\n                  under sorafenib therapy or intolerant to sorafenib, or;\n\n               -  intermediate HCC (BCLC-B) non eligible or non responders to transarterial\n                  chemoembolization (TACE), and having progressed under or intolerant to sorafenib\n                  therapy\n\n          -  HCC diagnosed according to the AASLD criteria:\n\n               -  Cyto-histology criteria and/or Non-invasive criteria\n\n          -  Without cirrhosis or with a non decompensated cirrhosis (Child-Pugh score from A5 to\n             B7 included);\n\n          -  ECOG Performance Status 0 or 1;\n\n          -  Laboratory tests as follows:\n\n               -  Platelets \u2265 50,000 /mm3\n\n               -  Neutrophil count \u2265 1000/mm3\n\n               -  Hemoglobin \u2265 10g/dL\n\n               -  Serum transaminases < 5 ULN (NCI/CTC grades 0, 1, or 2)\n\n               -  Alkaline phosphatases < 5 ULN (NCI/CTC grades 0, 1, or 2)\n\n               -  Serum bilirubin < 35 \u00b5M/L (or 2.0 mg/dL);\n\n          -  Signed and dated written informed consent form.\n\n        Exclusion Criteria:\n\n          -  Cirrhosis with a Child-Pugh score B8-C15;\n\n          -  Untreated chronic hepatitis B;\n\n          -  Patients eligible for curative treatments (transplantation, surgical resection,\n             percutaneous treatment);\n\n          -  Patients eligible for palliative treatments with demonstrated efficacy: TACE,\n             sorafenib (patients who failed to sorafenib treatment or intolerant to sorafenib can\n             be included);\n\n          -  HCC developed on transplanted liver;\n\n          -  HIV infection;\n\n          -  Risk of variceal bleeding;\n\n          -  SaO2 < 95%;\n\n          -  Presence of a significant acute or chronic respiratory disease, pleural effusion;\n\n          -  Presence of recent (< 6 months) or current cardiac failure (class III or IV NYHA\n             classification), recent (< 6 months) acute coronary syndrome, clinically significant\n             ECG abnormalities or recent (less than 6 months) acute vascular diseases (stroke,\n             MI\u2026);\n\n          -  Patients having undergone a 450 mg/m\u00b2 cumulated dose of doxorubicin;\n\n          -  Patients currently treated with immunosuppressive agents that cannot be stopped;\n\n          -  Patients with unstable ongoing medical/surgical problems;\n\n          -  Patients with a life expectancy of less than 2 months;\n\n          -  Patients who had participated in another clinical trial in the last 30 days;\n\n          -  Women of child-bearing age who are unwilling or unable to use an effective\n             contraception method during the study treatment period and for 2 months after the\n             last administration of study drug, and  their male partner(s) refusing to use a\n             condom (if applicable);\n\n          -  Men who are unwilling or unable to use a condom during the study treatment period and\n             for 2 months after the last administration of study drug, and their female partner(s)\n             refusing to use one of the appropriate effective contraception methods (if\n             applicable);\n\n          -  Patients unwilling or unable to comply with protocol requirements and scheduled\n             visits."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "390", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655693", 
            "org_study_id": "BA2011/03/04", 
            "secondary_id": "2011-002843-92"
        }, 
        "intervention": [
            {
                "arm_group_label": "Doxorubicin Transdrug (DT) at 20mg/m2", 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug", 
                "other_name": "Doxorubicin Transdrug (DT) at 20mg/m2"
            }, 
            {
                "arm_group_label": "Doxorubicin Transdrug (DT) at 30 mg/m2", 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug", 
                "other_name": "Doxorubicin Transdrug (DT) at 30mg/m2"
            }, 
            {
                "arm_group_label": "Best Supportive Care", 
                "intervention_name": "Best Supportive Care", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Doxorubicin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Intermediate/advanced hepatocellular carcinoma", 
            "After failure or intolerance to Sorafenib."
        ], 
        "lastchanged_date": "May 3, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France", 
                        "zip": "80054"
                    }, 
                    "name": "Hospital Amiens"
                }, 
                "investigator": {
                    "last_name": "Eric Nguyen-Khac, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France"
                    }, 
                    "name": "CHU"
                }, 
                "investigator": {
                    "last_name": "Paul CALES, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besan\u00e7on", 
                        "country": "France", 
                        "zip": "25000"
                    }, 
                    "name": "Hospital jean Minjoz"
                }, 
                "investigator": {
                    "last_name": "Vincent Di Martino", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33075"
                    }, 
                    "name": "Hospital Saint Andr\u00e9"
                }, 
                "investigator": {
                    "last_name": "Jean-Fr\u00e9d\u00e9rique Blanc, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }, 
                    "name": "CHU"
                }, 
                "investigator": {
                    "last_name": "Isabelle OLLIVIER-HOURMAND, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63003"
                    }, 
                    "name": "Hospital Estaing"
                }, 
                "investigator": {
                    "last_name": "Armand Abergel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "Hospital Henri-Mondor"
                }, 
                "investigator": {
                    "last_name": "Charlotte Costentin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France"
                    }, 
                    "name": "Centre Inter-Communal"
                }, 
                "investigator": {
                    "last_name": "Isabelle ROSA, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrick HILLON, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France"
                    }, 
                    "name": "CHU"
                }, 
                "investigator": {
                    "last_name": "Patrick HILLON, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Tronche", 
                        "country": "France", 
                        "zip": "38700"
                    }, 
                    "name": "Hospital Grenoble"
                }, 
                "investigator": {
                    "last_name": "Jean-Pierre Zarski, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France"
                    }, 
                    "name": "CHU Dupuytren"
                }, 
                "investigator": {
                    "last_name": "Nicole TUBIANA-MATHIEU, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69317"
                    }, 
                    "name": "Hospital Croix Rousse"
                }, 
                "investigator": {
                    "last_name": "Philippe Merle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13005"
                    }, 
                    "name": "Hospital La Conception"
                }, 
                "investigator": {
                    "last_name": "Santandrea Gerolami, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "Hospital Saint Eloi"
                }, 
                "investigator": {
                    "last_name": "Georges-Philippe Pageaux, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France", 
                        "zip": "54511"
                    }, 
                    "name": "Hospital Brabois"
                }, 
                "investigator": {
                    "last_name": "Jean Pierre Bronowicki, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "Hospital Hotel Dieu"
                }, 
                "investigator": {
                    "last_name": "Yann Touchefeu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France"
                    }, 
                    "name": "CHU - H\u00f4pital Archet"
                }, 
                "investigator": {
                    "last_name": "Albert TRAN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orleans", 
                        "country": "France", 
                        "zip": "45067"
                    }, 
                    "name": "Hospital La Source"
                }, 
                "investigator": {
                    "last_name": "Barbara Dauvois, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75013"
                    }, 
                    "name": "Hospital Piti\u00e9-Salpetriere"
                }, 
                "investigator": {
                    "last_name": "Vlad Ratziu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75020"
                    }, 
                    "name": "Hospital Tenon"
                }, 
                "investigator": {
                    "last_name": "Jean-Didier Grange, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Saint-Antoine"
                }, 
                "investigator": {
                    "last_name": "Olivier ROSMORDUC, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "HEGP"
                }, 
                "investigator": {
                    "last_name": "Julien TAIEB, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perpignan", 
                        "country": "France", 
                        "zip": "66046"
                    }, 
                    "name": "Hospital Saint Jean"
                }, 
                "investigator": {
                    "last_name": "Faiza Khemissa-Akouz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre Benite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Hospital Lyon Sud"
                }, 
                "investigator": {
                    "last_name": "Driffa Moussata, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Marc PHELIP, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-Etienne", 
                        "country": "France"
                    }, 
                    "name": "IC LOIRE"
                }, 
                "investigator": {
                    "last_name": "Jean-Marc PHELIP, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67091"
                    }, 
                    "name": "Hospital Civil"
                }, 
                "investigator": {
                    "last_name": "Michel Doffoel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94804"
                    }, 
                    "name": "Hospital Paul Brousse"
                }, 
                "investigator": {
                    "last_name": "Gilles Pelletier, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug\u2122 (DT) (20mg/m2 and 30mg/m2) to Those of Best Supportive Care (BSC) in Patients Suffering From Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study", 
        "overall_contact": {
            "email": "berangere.vasseur@bioalliancepharma.com", 
            "last_name": "Berangere Vasseur, MD", 
            "phone": "+33 (0)1 45 58 76 04"
        }, 
        "overall_official": {
            "affiliation": "Croix-Rousse Hospital - Lyon-France", 
            "last_name": "Philippe Merle, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Committee for the Protection of Personnes", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Survival status will be collected at each visit (at least every 2 weeks) during the study treatment period and then every 3 months until death for an expected average of 1 year.", 
            "measure": "Overall survival(OS) in each group", 
            "safety_issue": "No", 
            "time_frame": "at 1 year (expected average)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655693"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events will be collected at each visit (at least every 2 weeks) during the study treatment period, and then 2 months after the last treatment intake for an expected average of 6 months.", 
            "measure": "Incidence and severity of all Treatment Emergent Adverse Events according to NCI-CTC v4.0 scale in each groups", 
            "safety_issue": "Yes", 
            "time_frame": "until 2 months after last treatment intake"
        }, 
        "source": "BioAlliance Pharma SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioAlliance Pharma SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}